<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449098</url>
  </required_header>
  <id_info>
    <org_study_id>Mediking 0701</org_study_id>
    <secondary_id>OculusGen-2006-02-20</secondary_id>
    <nct_id>NCT00449098</nct_id>
  </id_info>
  <brief_title>Ologen (OculusGen)-Glaucoma MMC Control Trial in India</brief_title>
  <official_title>Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pro Top &amp; Mediking Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pro Top &amp; Mediking Company Limited</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of the ologen
      (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study Objective: To compare the safety and effectiveness of the ologen (OculusGen)
           Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery. The
           primary endpoint is to prove the effectiveness via the reduction of IOP, and the
           secondary endpoint is to prove the safety via the incidence of complications and adverse
           events.

        2. Study Design: The study is designed as an open-label, randomized, parallel, comparative
           study. Patients who meet the inclusion/exclusion criteria and sign informed consent will
           be included. After enrollment, patients will be randomized into two groups:
           trabeculectomy with ologen (OculusGen) implant or trabeculectomy with mitomycin-C.

        3. Follow-Up: There will be 7 post-operative and follow-up visits within 6 months of
           surgery: postoperative days 1, 7, 14, 30, 60, 90 and 180. A window of ± 7 days is
           allowed for the 30, 60, 90 day visits and ± 14 days for the 180 day visits. Further
           follow-up of subjects after the trial will be the responsibility of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effectiveness via the reduction of IOP</measure>
    <time_frame>180 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the safety via the incidence of complications and adverse events.</measure>
    <time_frame>180 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>OculusGen Biodegradable Collagen Matrix Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with MMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OculusGen Biodegradable Collagen Matrix Implant</intervention_name>
    <description>Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant</description>
    <arm_group_label>OculusGen Biodegradable Collagen Matrix Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabeculectomy with MMC</intervention_name>
    <description>Trabeculectomy with MMC</description>
    <arm_group_label>MMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over.

          -  Uncontrolled glaucoma, with failed medical and laser treatment, requiring
             trabeculectomy.

          -  Subject able and willing to cooperate with investigation plan.

          -  Subject able and willing to complete postoperative follow-up requirements.

          -  Subject willing to sign informed consent form.

        Exclusion Criteria:

          -  Known allergic reaction to mitomycin-C or porcine collagen.

          -  Subject is on warfarin and discontinuation is not recommended.

          -  Normal tension glaucoma.

          -  Participation in an investigational study during the 30 days preceding trabeculectomy.

          -  Ocular infection within 14 days prior to trabeculectomy.

          -  Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajul S Parikh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>V. S. T. Glaucoma Services, L. V. Prasad Eye Institute,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arslan Tsai, Pharma</last_name>
    <phone>+886 2 27088558</phone>
    <phone_ext>116</phone_ext>
    <email>arslan.tsai@aeonastron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>L. V. Prasad Eye Institute</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Prades</state>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajul S Parikh, MD</last_name>
      <phone>+91 40 3061 2345</phone>
      <email>rajulparikh@lvpei.org</email>
    </contact>
    <contact_backup>
      <last_name>G Chandrasekhar, MD</last_name>
      <phone>+91 40 3061 2345</phone>
      <email>gcs@lvpei.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anil Mandal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>G Chandrasekhar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajul S Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Chen HS, Ritch R, Krupin T, Hsu WC. Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5310-4. Erratum in: Invest Ophthalmol Vis Sci. 2007 Feb;48(2):485.</citation>
    <PMID>17122118</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11.</citation>
    <PMID>10937547</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <last_update_submitted>October 6, 2011</last_update_submitted>
  <last_update_submitted_qc>October 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Collagen matrix</keyword>
  <keyword>ologen</keyword>
  <keyword>OculusGen</keyword>
  <keyword>Trabeculectomy</keyword>
  <keyword>anti scarring</keyword>
  <keyword>tissue engineering</keyword>
  <keyword>high risk patient for trabeculectomy</keyword>
  <keyword>Aeon Astron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

